Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ907MR)

This product GTTS-WQ907MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ907MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1402MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ13758MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ13064MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ5775MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ7922MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ12497MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ1237MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ12991MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW